Menu
Back to User profile » Dr Siraj M Ali
Papers published by Dr Siraj M Ali:
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR
Lung Cancer: Targets and Therapy 2019, 10:81-86
Published Date: 15 August 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Zhu VW, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2019, 10:21-26
Published Date: 12 March 2019
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2018, 9:111-116
Published Date: 8 November 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
Parikh AR, Ali SM, Schrock AB, Albacker LA, Miller VA, Stephens PJ, Crilley P, Markman M
Lung Cancer: Targets and Therapy 2018, 9:45-47
Published Date: 18 May 2018
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
Williams CB, McMahon C, Ali SM, Abramovitz M, Williams KA, Klein J, McKean H, Yelensky R, George Jr TJ, Elvin JA, Soman S, Lipson D, Chmielecki J, Morosini D, Miller VA, Stephens PJ, Ross JS, Leyland-Jones B
OncoTargets and Therapy 2015, 8:3561-3564
Published Date: 1 December 2015